


Erucic acid

Cat. No.:	HY-N7109												
CAS No.:	112-86-7												
Molecular Formula:	C ₂₂ H ₄₂ O ₂												
Molecular Weight:	338.57												
Target:	PI3K; Endogenous Metabolite												
Pathway:	PI3K/Akt/mTOR; Metabolic Enzyme/Protease												
Storage:	<table border="0"> <tr> <td>Pure form</td> <td>-20°C</td> <td>3 years</td> </tr> <tr> <td></td> <td>4°C</td> <td>2 years</td> </tr> <tr> <td>In solvent</td> <td>-80°C</td> <td>6 months</td> </tr> <tr> <td></td> <td>-20°C</td> <td>1 month</td> </tr> </table>	Pure form	-20°C	3 years		4°C	2 years	In solvent	-80°C	6 months		-20°C	1 month
Pure form	-20°C	3 years											
	4°C	2 years											
In solvent	-80°C	6 months											
	-20°C	1 month											



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 100 mg/mL (295.36 mM)
 * "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	2.9536 mL	14.7680 mL	29.5360 mL
	5 mM	0.5907 mL	2.9536 mL	5.9072 mL
	10 mM	0.2954 mL	1.4768 mL	2.9536 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
 Solubility: ≥ 2.5 mg/mL (7.38 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
 Solubility: 2.5 mg/mL (7.38 mM); Suspended solution; Need ultrasonic
- Add each solvent one by one: 10% DMSO >> 90% corn oil
 Solubility: ≥ 2.5 mg/mL (7.38 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Erucic acid, a monounsaturated fatty acid (MUFA), is isolated from the seed of *Raphanus sativus* L. Erucic acid can readily cross the blood-brain barrier (BBB), it has been reported to normalize the accumulation of very long-chain fatty acids in the brain. Erucic acid can improve cognitive impairment and be effective against dementia^[1].

In Vivo

Erucic acid (oral administration; 3 mg/kg) enhances the phosphorylation level of PI3K, PKCζ, ERK, CREB and Akt in the hippocampus compared with that in the vehicle-treated control group^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Normal naïve mice ^[1]
Dosage:	3 mg/kg
Administration:	Oral administration; 3 mg/kg
Result:	Enhanced the phosphorylation level of PI3K, PKCζ, ERK, CREB and Akt in the hippocampus.

REFERENCES

[1]. Kim E, et al. The memory-enhancing effect of erucic acid on scopolamine-induced cognitive impairment in mice. *Pharmacol Biochem Behav.* 2016 Mar;142:85-90.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA